Monday, December 23, 2024
HomeTagsJanssen’s Bispecific

Janssen’s Bispecific

Updated Data for Janssen’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study.1 Teclistamab is an...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics